abstract
This policy statement provides recommendations for the prevention of serogroup B meningococcal disease through the use of 2 newly licensed serogroup B meningococcal vaccines: MenB-FHbp (Trumenba; Wyeth Pharmaceuticals, a subsidiary of Pfi zer, Philadelphia, PA) and MenB-4C (Bexsero; Novartis Vaccines, Siena, Italy). Both vaccines are approved for use in persons 10 through 25 years of age. MenB-FHbp is licensed as a 2-or 3-dose series, and MenB-4C is licensed as a 2-dose series for all groups. Either vaccine is recommended for routine use in persons 10 years and older who are at increased risk of serogroup B meningococcal disease (category A recommendation). Persons at increased risk of meningococcal serogroup B disease include the following: (1) persons with persistent complement component diseases, including inherited or chronic defi ciencies in C3, C5-C9, properdin, factor D, or factor H or persons receiving eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, CT), a monoclonal antibody that acts as a terminal complement inhibitor by binding C5 and inhibiting cleavage of C5 to C5A; (2) persons with anatomic or functional asplenia, including sickle cell disease; and (3) healthy persons at increased risk because of a serogroup B meningococcal disease outbreak. Both serogroup B meningococcal vaccines have been shown to be safe and immunogenic and are licensed by the US Food and Drug Administration for individuals between the ages of 10 and 25 years. On the basis of epidemiologic and antibody persistence data, the American Academy of Pediatrics agrees with the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention that either vaccine may be administered to healthy adolescents and young adults 16 through 23 years of age (preferred ages are 16 through 18 years) to provide short-term protection against most strains of serogroup B meningococcal disease (category B recommendation). A majority of these (80%) occur in individuals 16 through 23 years of age (CDC, unpublished data). Despite a number of recent outbreaks on college campuses, the incidence of serogroup B meningococcal disease in college students (0.09 per 100 000) is similar to or lower than the incidence in all 18-through 23-year-olds (0.14 per 100 000) and noncollege students (0.21 per 100 000) (CDC, unpublished data). A routine adolescent MenB vaccine recommendation would be estimated to prevent 15 to 29 cases and 2 to 5 deaths per year, assuming that all eligible persons were immunized. A recommendation for routine MenB vaccination of college students only is estimated to prevent 10 cases and 1 death per year (CDC, unpublished data).
INTRODUCTION
Certain individuals are known to have an increased susceptibility to invasive meningococcal disease. 1 These individuals are currently recommended to be vaccinated with a quadrivalent meningococcal conjugate vaccine (MenACWY). 1 Many, but not all, of these groups are also at increased risk of invasive disease attributable to N meningitidis serogroup B ( Table 1) . Persons with persistent complement component deficiencies, including inherited or chronic deficiencies in C3, C5-C9, properdin, factor D, or factor H, have up to a 10 000-fold increased risk of meningococcal disease and can experience recurrent disease. 1, 2 Individuals receiving eculizumab (Soliris; Alexion Pharmaceuticals, Cheshire, CT), a monoclonal antibody that binds to C5 and inhibits the terminal portion of the complement pathway, are at increased risk of invasive meningococcal disease, including serogroup B meningococcus. 3 Eculizumab is approved for the treatment of atypical hemolytic-uremic syndrome and paroxysmal nocturnal hemoglobinuria. 3 Five of 326 subjects (1.5%) in clinical trials of eculizumab developed invasive meningococcal disease despite previous immunization with a meningococcal vaccine. 3 The package insert does not describe the serogroups of these 5 meningococcal infections. 3 However, serogroup B meningococcal disease in eculizumab recipients has been described. Persons with functional or anatomic asplenia, including sickle cell disease, appear to be at increased risk of invasive meningococcal disease and have a higher case fatality rate (40%-70%) from meningococcal disease than healthy populations. 4 The increased risk of meningococcal infection in patients with asplenia is less than that for invasive pneumococcal disease. 1 Data describing immune responses to MenB vaccines in populations with complement deficiency and asplenia have not yet been published. Microbiologists who routinely work with N meningitidis have an attack rate of 13 per 100 000. This attack rate in microbiologists is severalfold higher than that in the general population. 1 Because microbiologists are not in the pediatric age range, recommendations for microbiologists will not be included in recommendations from the American Academy of Pediatrics (AAP) but are included in the ACIP recommendations.
The vast majority of all cases of meningococcal disease occurring in the United States are sporadic (97%-98%). However, outbreaks of meningococcal disease continue to occur and often receive media attention because of the severity of invasive meningococcal disease. In recent years, outbreaks of serogroup B meningococcal disease have occurred on several different college campuses. Data from 2 recent outbreaks on college campuses (spring 2013 through spring 2014) noted a 200-to 1400-fold increase in risk of meningococcal disease among students at these colleges during the outbreak period (CDC, unpublished data).
A comparison of risk groups for the quadrivalent meningococcal conjugate vaccine and the recently licensed serogroup B meningococcal vaccines is presented in Table  1 . 1 College students have a lower risk of serogroup B meningococcal disease than the general population of a similar age (college students compared with 18-through 23-year-olds: 0.09 per 100 000 and 0.14 per 100 000, respectively). 16 and for MenACWY and tetanus, diphtheria, and pertussis antigens (unpublished data) when MenB-FHbp was administered concomitantly. For HPV-18, noninferiority criteria (lower bound of the 95% confidence interval of geometric mean titer [GMT] ratio >0.67) were not met for the GMT ratio at 1 month after the third quadrivalent HPV vaccination (lower bound of 95% confidence interval for GMT ratio was 0.62); however, for each HPV vaccine type, more than 99% of subjects achieved seroconversion. 16 In clinical trials, both MenB vaccines were safe, with few serious adverse events (all resolved without sequelae). 7 -16 There were no deaths considered to be related to either vaccine. Local and systemic adverse events noted in clinical trials are included in Table 2 and young adults is based on the very low incidence of serogroup B meningococcal disease in persons who are not at high risk and lack of availability of certain data that would be valuable in developing policy. For these reasons, the ACIP determined that there were insufficient data to make a routine recommendation that all adolescents be vaccinated with an MenB vaccine. The AAP also considered the difficulty of delivering multiple vaccine doses to adolescents, the cost of the vaccine series, and the unfavorable costeffectiveness evaluation (ACIP meeting, unpublished data, June 2015; methods described in MacNeil et al 18 ; Table 3 ) while developing these recommendations. This restrictive recommendation allows treating clinicians to determine which adolescents and young adults might receive benefit from receiving a series of one of the MenB vaccines. If the clinician and family discuss the MenB vaccine and the MenB vaccine is not administered, the discussion and decision should be documented in the patient's health record. 
PRECAUTIONS AND CONTRAINDICATIONS
Before administering MenB vaccines, treating clinicians should consult the package insert for a 5 
